Literature DB >> 33510340

Prevalence and characteristics of cutaneous allodynia in probable migraine.

Seung Min Han1, Kyung Min Kim2, Soo-Jin Cho3, Kwang Ik Yang4, Daeyoung Kim5, Chang-Ho Yun6, Min Kyung Chu7.   

Abstract

Cutaneous allodynia (CA) is a pain in response to non-nociceptive stimulation and a marker of central sensitisation. Probable migraine (PM) is a migraine subtype that fulfils all but one criterion of migraine. Headache intensity and the disability of individuals with PM are similar or lower than individuals with migraine. This study compared CA prevalence and characteristics of PM and migraine using a nationally representative sample in Korea. The Allodynia Symptom Checklist-12 (ASC-12) was used to assess CA (ASC-12 score ≥ 3). PM and migraine prevalence were 11.6% and 5.0%, respectively. CA prevalence did not significantly differ between PM and migraine (14.5% vs. 16.0%, p = 0.701). Participants with PM with CA reported a higher monthly headache frequency (3.3 ± 4.3 vs. 1.8 ± 3.6, p = 0.044), more severe headache intensity (Visuals Analogue Scale, 6.0 [4.0-7.0] vs. 5.0 [3.0-6.0], p = 0.002), and higher impact of headache (Headache Impact Test-6, 56.3 ± 7.2 vs. 48.3 ± 8.0, p < 0.001) than those without CA. Multiple regression analyses revealed that headache frequency and intensity, anxiety, and depression were significant factors for CA in participants with PM. In conclusion, CA prevalence among participants with PM and migraine were comparable. Anxiety, depression, and headache frequency and intensity were significant factors for CA in participants with PM.

Entities:  

Year:  2021        PMID: 33510340     DOI: 10.1038/s41598-021-82080-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  46 in total

1.  Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study.

Authors:  David W Dodick; Michael L Reed; Kristina M Fanning; Sagar Munjal; Aftab Alam; Dawn C Buse; Todd J Schwedt; Richard B Lipton
Journal:  Cephalalgia       Date:  2019-02-07       Impact factor: 6.292

2.  Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain.

Authors:  B J Sessle; J W Hu; N Amano; G Zhong
Journal:  Pain       Date:  1986-11       Impact factor: 6.961

3.  The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine.

Authors:  R Burstein; M F Cutrer; D Yarnitsky
Journal:  Brain       Date:  2000-08       Impact factor: 13.501

Review 4.  Central sensitization: implications for the diagnosis and treatment of pain.

Authors:  Clifford J Woolf
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

5.  Allodynia in migraine: association with comorbid pain conditions.

Authors:  Gretchen E Tietjen; Jan L Brandes; B Lee Peterlin; Arnolda Eloff; Rima M Dafer; Michael R Stein; Ellen Drexler; Vincent T Martin; Susan Hutchinson; Sheena K Aurora; Ana Recober; Nabeel A Herial; Christine Utley; Leah White; Sadik A Khuder
Journal:  Headache       Date:  2009-10       Impact factor: 5.887

6.  Prevalence and characteristics of allodynia in headache sufferers: a population study.

Authors:  M E Bigal; S Ashina; R Burstein; M L Reed; D Buse; D Serrano; R B Lipton
Journal:  Neurology       Date:  2008-04-22       Impact factor: 9.910

Review 7.  Quantitative sensory testing with Von Frey monofilaments in patients with allodynia: what are we quantifying?

Authors:  Doeke Keizer; David Fael; Jan Mark K H Wierda; Marten van Wijhe
Journal:  Clin J Pain       Date:  2008-06       Impact factor: 3.442

8.  Cutaneous allodynia as a predictor of migraine chronification.

Authors:  Mark A Louter; Johanneke E Bosker; Willebrordus P J van Oosterhout; Erik W van Zwet; Frans G Zitman; Michel D Ferrari; Gisela M Terwindt
Journal:  Brain       Date:  2013-09-29       Impact factor: 13.501

9.  Cutaneous allodynia in the migraine population.

Authors:  Richard B Lipton; Marcelo E Bigal; Sait Ashina; Rami Burstein; Stephen Silberstein; Michael L Reed; Daniel Serrano; Walter F Stewart
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

10.  Neurological Assessment Using a Quantitative Sensory Test in Patients with Chronic Unilateral Orofacial Pain.

Authors:  Talal H Salame; Antony Blinkhorn; Zahra Karami
Journal:  Open Dent J       Date:  2018-01-31
View more
  5 in total

1.  TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine.

Authors:  David Alarcón-Alarcón; David Cabañero; Jorge de Andrés-López; Magdalena Nikolaeva-Koleva; Simona Giorgi; Gregorio Fernández-Ballester; Asia Fernández-Carvajal; Antonio Ferrer-Montiel
Journal:  Nat Commun       Date:  2022-10-22       Impact factor: 17.694

2.  CGRP Administration Into the Cerebellum Evokes Light Aversion, Tactile Hypersensitivity, and Nociceptive Squint in Mice.

Authors:  Mengya Wang; Thomas L Duong; Brandon J Rea; Jayme S Waite; Michael W Huebner; Harold C Flinn; Andrew F Russo; Levi P Sowers
Journal:  Front Pain Res (Lausanne)       Date:  2022-04-25

3.  Association of Migraine with Its Comorbidities and Food Specific Immunoglobulin G Antibodies and Inflammatory Cytokines: Cross-Sectional Clinical Research.

Authors:  Zhiming Zhao; Huiwen Jin; Yang Yin; Yanwei Hou; Jingyan Wang; Chunling Tang; Jun Fu
Journal:  J Pain Res       Date:  2021-08-05       Impact factor: 3.133

4.  Prevalence and impact of visual aura in migraine and probable migraine: a population study.

Authors:  Kyung Min Kim; Byung-Kun Kim; Wonwoo Lee; Heewon Hwang; Kyoung Heo; Min Kyung Chu
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.996

Review 5.  Cutaneous Allodynia in Migraine: A Narrative Review.

Authors:  Ane Mínguez-Olaondo; Sonia Quintas; Noemí Morollón Sánchez-Mateos; Alba López-Bravo; Marta Vila-Pueyo; Vesselina Grozeva; Robert Belvís; Sonia Santos-Lasaosa; Pablo Irimia
Journal:  Front Neurol       Date:  2022-01-21       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.